pliantrx.com (PLRX) Cash per Single Share

The cash per share chart for Pliant Therapeutics (PLRX) demonstrates volatility driven by the fierce competition for leadership in fibrosis therapy. 2.27 shows the current value of this metric. This price action reflects a total reliance on external contractors for substance synthesis and a lack of commercial products, leaving the company dependent on investment until clinical trials are completed.
Comprehensive metric breakdowns and analytics for Pliant Therapeutics, Inc. (PLRX)

Cash per share measures the volume of liquid assets attributable to a single security, determining the business's intrinsic margin of safety. For Pliant Therapeutics (PLRX), this resource is critical, as the automation of drug synthesis requires constant funding for prolonged clinical trials. By analyzing the current cash per share level, an investor assesses the company's ability to cover operating expenses without additional share offerings. High liquidity minimizes bankruptcy risk during periods of market volatility. This indicator confirms the financial stability of the biopharmaceutical startup.